DANIEL R. PASSERI - 21 Jul 2023 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Daniel Passeri by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
21 Jul 2023
Net transactions value
$0
Form type
4
Filing time
25 Jul 2023, 12:28:37 UTC
Previous filing
21 Feb 2023
Next filing
16 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +450,000 $0.000000 450,000 21 Jul 2023 Common Stock 450,000 $4.20 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023.